$RARE

Kahn Swick & Foti, LLC filed class action lawsuits against Navan, Kyndryl, and Ultragenyx for alleged securities disclosure violations. Lead plaintiff applications due April 24, 2026.

Class action lawsuit filed against $UGXY alleging securities fraud related to setrusumab clinical trial data. Investors from August 2023 to December 2025 eligible.

Ultragenyx faces securities lawsuit over delayed disclosure of failed Phase 3 trial. Investors must file lead plaintiff claims by April 6, 2026.

Portnoy Law Firm filed securities class action against Ultragenyx Pharmaceutical, alleging the company made false statements about investigational drug setrusumab and concealed material clinical trial risks.

Ultragenyx faces securities lawsuit after failing to disclose setrusumab trial failure, causing 42% stock drop. Investors claim company withheld material information before December announcement.

Ultragenyx faces securities lawsuit alleging false claims about drug setrusumab for bone disease. Investors have until April 6, 2026 deadline to join class action.

Ultragenyx faces class action lawsuit for allegedly misleading investors about setrusumab efficacy and failing to disclose Phase III trial risks adequately.

Class action lawsuits filed against Ultragenyx and Mereo after Phase III clinical trials for setrusumab failed. Stock prices plummeted 42% and 88% respectively following the announcement.

Rosen Law Firm sues Ultragenyx for securities fraud, alleging executives misrepresented drug efficacy. Investors who bought stock August 2023-December 2025 can claim damages by April 6, 2026 deadline.

Ultragenyx Pharmaceutical faces class action lawsuit for allegedly making false statements about setrusumab drug efficacy and safety, affecting investors who bought securities between August 2023 and December 2025.

Ultragenyx faces class action lawsuit alleging false statements about its osteogenesis imperfecta drug's efficacy after Phase III trial failed to meet primary endpoint.

Ultragenyx faces securities lawsuit alleging misleading claims about setrusumab's efficacy. Investors must act by April 6, 2026 deadline to join class action.